Journal Article10.1007/s40005-022-00583-x
A comprehensive review on different approaches for tumor targeting using nanocarriers and recent developments with special focus on multifunctional approaches
21
TL;DR: The newer generation nanocarriers need a more multifunctional approach, combining active targeting with immunotherapy and diagnostic contrast agent delivery, and there is a need of finding new cancer markers, toxicity studies, and scale-up approaches to these nanosystems.
read more
About: This article is published in Journal of pharmaceutical investigation. The article was published on 28 Jul 2022. The article focuses on the topics: Nanocarriers.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Liposomal Iron Oxide Nanoparticles Loaded with Doxorubicin for Combined Chemo-Photothermal Cancer Therapy
TL;DR: In this article , the authors developed doxorubicin (DOX)-loaded liposomal IONP (Lipo-IONP/DOX) and evaluated in vitro and in vivo their applicability for combined chemo-photothermal cancer therapy.
Precise subcellular targeting approaches for organelle-related disorders
Gayong Shim,Yu Seok Youn +1 more
TL;DR: This review discusses the basic concepts of organelle targeting research and proposes strategies to target diseases arising from organelle dysfunction, and addresses the current challenges faced by organelle targeting.
8
Development and characterization of pH-responsive dual drug-loaded nanocarriers for chemo-photothermal combination therapy of acidic tumors.
Patihul Husni,Yuseon Shin,Hye-Jin Jeon,Eun Seong Lee,Yu Seok Youn,Chi-Duen Poon,Chaemin Lim,Kyung Taek Oh +7 more
TL;DR: In this article , a simple pH-sensitive chemo-photothermal combination agent capable of repeated exposures to a near-infrared (NIR) laser and evaluated its anticancer efficacy in vitro and in vivo.
8
Effects of PEG-Linker Chain Length of Folate-Linked Liposomal Formulations on Targeting Ability and Antitumor Activity of Encapsulated Drug
TL;DR: In this paper , the effect of the length of the PEG-linker on the nanoparticle distribution and pharmacological efficacy of the encapsulated drug was evaluated both in vitro and in vivo.
6
Tumor extracellular vesicles carrying antitumor (KLAKLAK)2 peptide and tumor-specific antigens for improved tumor therapy
Eunsol Lee,Eun Seong Lee +1 more
TL;DR: Results indicate that the bEVs can provide a synergistic effect compared to single EV administration, and are demonstrated to be effective in vitro/in vivo tumor model studies.
5
References
Enzyme-sensitive biodegradable and multifunctional polymeric conjugate as theranostic nanomedicine
TL;DR: The theranostic nanomedicine derived from the enzyme-sensitive biodegradable pHPMA-Gd-PTX-Cy5.5 conjugate may open a door for simultaneous therapeutic treatment and MR imaging of breast cancer.
118
Intratumoral Delivery of Doxorubicin on Folate-Conjugated Graphene Oxide by In-Situ Forming Thermo-Sensitive Hydrogel for Breast Cancer Therapy.
TL;DR: GOFA-DOX/HACPN could be deemed as a safe and efficient intratumoral drug delivery system for breast cancer therapy because of its anti-tumor efficacy and the targeting effect of FA, which resulted in enhanced in vitro cytotoxicity.
112
Folate Receptor-Targeted and GSH-Responsive Carboxymethyl Chitosan Nanoparticles Containing Covalently Entrapped 6-Mercaptopurine for Enhanced Intracellular Drug Delivery in Leukemia.
Xuan Wei,Jianhong Liao,Zahra Davoudi,Hua Zheng,Jingru Chen,Dan Li,Xiong Xiong,Yihua Yin,Xiuxiang Yu,Jinghui Xiong,Qun Wang +10 more
TL;DR: It is suggested that folate receptor-targeting and GSH-stimulation can significantly elevate tumour intracellular drug release and therefore, folate-modified nanoparticles containing chemoradiotherapy is a potential treatment for leukemia therapy.
109
Breaking in and busting out: cell-penetrating peptides and the endosomal escape problem.
TL;DR: Are the authors on the verge of developing technologies to deliver therapeutics such as siRNA, CRISPR/Cas complexes and others that are currently failing because of an inability to get into cells, or are they just chasing after another promising but unworkable technology?
Current State of Dendritic Cell-Based Immunotherapy: Opportunities for in vitro Antigen Loading of Different DC Subsets?
TL;DR: In this article, the authors discuss cellular aspects essential for DC vaccination efficacy, and the most recent findings on different DC subsets that could be used for DC-based cancer immunotherapy.